{"id":994624,"date":"2026-08-13T06:34:22","date_gmt":"2026-08-13T10:34:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/22nd-century-group-reports-second-quarter-2026-financial-results\/"},"modified":"2026-08-13T06:34:22","modified_gmt":"2026-08-13T10:34:22","slug":"22nd-century-group-reports-second-quarter-2026-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/22nd-century-group-reports-second-quarter-2026-financial-results\/","title":{"rendered":"22nd Century Group Reports Second Quarter 2026 Financial Results"},"content":{"rendered":"
\n

\n Advances VLN<\/i>
\n
\n \u00ae<\/i>
\n <\/sup>
\n Commercialization Through Expanded Retail Support and Brand-Building Initiatives<\/i>\n <\/p>\n

\n MOCKSVILLE, N.C., Aug. 13, 2026 (GLOBE NEWSWIRE) — <\/strong>22nd Century Group, Inc. (Nasdaq: XXII), the leader in low-nicotine tobacco, low-nicotine cigarettes and only tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced results for the second quarter ended June 30, 2026, and provided an update on recent commercial, regulatory and operational activities.<\/p>\n

The Company\u2019s proprietary reduced nicotine technology is designed to serve adult smokers seeking to significantly reduce nicotine consumption while continuing to use a familiar combustible format. 22nd Century\u2019s strategy is centered on providing adult smokers with FDA-authorized reduced nicotine cigarette products intended to help them take greater control of their nicotine consumption.<\/p>\n

\u201cThe second quarter marked another period of disciplined execution as we continued to expand retail distribution, increase consumer awareness and strengthen the commercial foundation for our VLN\u00ae<\/sup> cigarette products\u201d said Larry Firestone, Chief Executive Officer of 22nd Century Group. \u201cDuring the quarter, we broadened our retail footprint, launched new Pinnacle\u00ae<\/sup> products, expanded into new geographic markets and continued building the infrastructure necessary to support long-term commercial growth. Our initial same-store sales reports for VLN\u00ae<\/sup> products demonstrated encouraging consumer demand and reinforced our belief that the market is looking for an alternative in the form of a combustible cigarette with significantly reduced nicotine.\u201d<\/p>\n

\u201cOur strategy remains straightforward. We will leverage our proprietary reduced-nicotine technology across multiple channels while improving economics through a broader product portfolio, add additional partner-brand opportunities and execute with discipline. As THE leader in low-nicotine tobacco technology and products, we believe our FDA-authorized modified risk claims, growing retail presence and differentiated intellectual property position us to continue investing in low-nicotine products and expanding the low-nicotine category. Together, these advantages provide us with a differentiated position within the tobacco industry and a strong foundation for future growth.\u201d<\/p>\n

\u201cWe believe nicotine reduction represents the next significant step in the evolution of the tobacco industry and one of the most compelling long-term opportunities in tobacco harm reduction. With our proprietary technology, FDA-authorized products, increasing commercial distribution and scalable business model, we believe 22nd Century is well positioned to create long-term value for adult smokers seeking familiar alternatives while delivering value for our shareholders.\u201d<\/p>\n

\n Second Quarter 2026 Financial Results <\/b>(compared to First Quarter 2026, except as noted)<\/p>\n

All figures reported below reflect continuing operations, excluding discontinued operations related to the sale and exit of the Company\u2019s hemp\/cannabis business in late 2023, except as noted.<\/p>\n\n\n\n\n\n\n\n\n\n
\u00a0<\/td>\n\u25cf<\/td>\nNet revenues decreased to $2.9 million from $4.1 million.<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u25cf<\/td>\nGross profit (loss) improved to $(0.3) million, compared to $(0.6) million.<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u25cf<\/td>\nOperating expenses were $3.0 million, increased from $2.4 million.<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u25cf<\/td>\nOperating loss increased to $3.3 million, compared to $3.0 million.<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u25cf<\/td>\nNet loss was $3.3 million, compared to net loss of $3.0 million.<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u25cf<\/td>\nAdjusted EBITDA loss was $3.5 million, compared to a loss of $2.6 million.<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u25cf<\/td>\nEnded the quarter with cash and cash equivalents of $6.1 million.<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n 2026 Strategic Priorities<\/b>\n <\/p>\n

22nd Century has identified the below priorities for its business activities in 2026:<\/p>\n\n\n\n\n\n\n
\u00a0<\/td>\n\u25cf<\/td>\nExpanding VLN\u00ae<\/sup> product distribution and consumer awareness.<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u25cf<\/td>\nContinuing disciplined cost management and capital allocation.<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u25cf<\/td>\nAdvancing toward EBITDA breakeven as higher-margin revenues scale.<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u25cf<\/td>\nRemaining actively engaged with FDA regulators and public-health stakeholders.<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

The Company believes that the convergence of regulatory momentum, increasing consumer awareness and its differentiated product portfolio may support long-term value creation.<\/p>\n

\n Recent Business Highlights<\/b>\n <\/p>\n